Leukemia Clinical Trials
Here are the 6 most popular medical studies for leukemia
Monoclonal Antibodies
Tocilizumab for Blood Cancer
This trial is testing whether the addition of the drug tocilizumab to the standard approach for GVHD prevention can reduce the risk of developing GVHD and GVHD-related complications. Tocilizumab works by blocking the effect of Interleukin-6, a protein that is elevated in the blood during periods of inflammation. This could potentially decrease the risk of developing GVHD and GVHD-associated complications.
JAK Inhibitor
Ruxolitinib + Chemotherapy for Acute Lymphoblastic Leukemia
This trial is testing a new cancer drug, ruxolitinib, in combination with standard chemotherapy to treat B-cell acute lymphoblastic leukemia. The study will first find the best dose of ruxolitinib to use with chemotherapy, then test how well the combination works at that dose.
Cell Therapy
T Cell Depletion for Blood Cancers
This trial is testing a new stem cell transplantation method for people with blood cancers. The new method uses a machine to remove certain cells from the donor stem cells, and it also removes a different type of cell from the patient before transplant. The trial will measure how well the transplant works and how long the patient survives without the cancer coming back.
IDH2 Inhibitor
Enasidenib for Chronic Myelomonocytic Leukemia
This trial will test if a new drug, enasidenib, is safe and effective in people with lower risk myelodysplastic syndrome or nonproliferative chronic myelomonocytic leukemia. The drug will be given to people who do not have a mutation in isocitrate dehydrogenase type 2.
Popular filter options for leukemia trials
Monocytic Leukemia Clinical Trials
View 71 Monocytic Leukemia medical studies.
Virus Therapy
SARS-CoV-2 Vaccine for Blood Cancers
This trial is studying a new vaccine, COH04S1, to see if it is better than the EUA SARS-CoV-2 vaccine in reducing the chances of contracting COVID-19 or developing a severe form of COVID-19 disease in patients with blood cancer who have received stem cell transplant or cellular therapy.
CAR T-cell Therapy
Kappa CD28 T cells for Blood Cancers
This trial is testing a new treatment for patients with a type of cancer called NHL, Multiple Myeloma (MM) or CLL that has come back or has not gone away after treatment. The treatment is a gene transfer research study using special immune cells. The study is testing whether combining two different ways of fighting disease, antibodies and T cells, will be more effective than using either method alone.
Acute Lymphoblastic Leukemia Clinical Trials
View 70 Acute Lymphoblastic Leukemia medical studies.
Virus Therapy
SARS-CoV-2 Vaccine for Blood Cancers
This trial is studying a new vaccine, COH04S1, to see if it is better than the EUA SARS-CoV-2 vaccine in reducing the chances of contracting COVID-19 or developing a severe form of COVID-19 disease in patients with blood cancer who have received stem cell transplant or cellular therapy.
CAR T-cell Therapy
Kappa CD28 T cells for Blood Cancers
This trial is testing a new treatment for patients with a type of cancer called NHL, Multiple Myeloma (MM) or CLL that has come back or has not gone away after treatment. The treatment is a gene transfer research study using special immune cells. The study is testing whether combining two different ways of fighting disease, antibodies and T cells, will be more effective than using either method alone.
Metastatic Leukemia Clinical Trials
View 77 metastatic leukemia medical studies.
CAR T-cell Therapy
Autologous T Cells Targeting CD19 for Chronic Lymphocytic Leukemia
This trial is testing whether using a patient's own T cells, which have been treated in the lab, can help the body build an effective immune response to kill cancer cells.
Bruton's Tyrosine Kinase (BTK) Inhibitor
PCI-32765 for Lymphocytic Leukemia
This trial is testing a new cancer treatment drug, PCI-32765, to see if it can treat chronic lymphocytic leukemia and small lymphocytic lymphoma in elderly people and people with 17p deletion.
BRAF Inhibitor
Vemurafenib + Obinutuzumab for Classical Hairy Cell Leukemia
This trial is testing a combination of two drugs, vemurafenib and obinutuzumab, to treat hairy cell leukemia (HCL) that has not been treated before. The trial will have 28 patients total, and will test the efficacy of the combination treatment. If the treatment is successful, bone marrow aspirate and biopsy will be performed to assess response and evaluate minimal residual disease (MRD).
CD19 Positive Clinical Trials
View 8 CD19 positive medical studies.
CAR T-cell Therapy
Autologous T Cells Targeting CD19 for Chronic Lymphocytic Leukemia
This trial is testing whether using a patient's own T cells, which have been treated in the lab, can help the body build an effective immune response to kill cancer cells.
Bruton's Tyrosine Kinase (BTK) Inhibitor
PCI-32765 for Lymphocytic Leukemia
This trial is testing a new cancer treatment drug, PCI-32765, to see if it can treat chronic lymphocytic leukemia and small lymphocytic lymphoma in elderly people and people with 17p deletion.
Leukemia Clinical Trials With No Placebo
View 77 leukemia medical studies that do not have a placebo group.
Virus Therapy
SARS-CoV-2 Vaccine for Blood Cancers
This trial is studying a new vaccine, COH04S1, to see if it is better than the EUA SARS-CoV-2 vaccine in reducing the chances of contracting COVID-19 or developing a severe form of COVID-19 disease in patients with blood cancer who have received stem cell transplant or cellular therapy.
CAR T-cell Therapy
Kappa CD28 T cells for Blood Cancers
This trial is testing a new treatment for patients with a type of cancer called NHL, Multiple Myeloma (MM) or CLL that has come back or has not gone away after treatment. The treatment is a gene transfer research study using special immune cells. The study is testing whether combining two different ways of fighting disease, antibodies and T cells, will be more effective than using either method alone.
View More Leukemia Trials
See another 49 many medical studies focused on leukemia.
Frequently Asked Questions
Introduction to leukemia
What are the top hospitals conducting leukemia research?
When it comes to cutting-edge clinical trials in the battle against leukemia, several hospitals across the United States are leading the way. In Houston, M D Anderson Cancer Center stands out with nine active leukemia trials and an impressive 209 completed trials throughout its history. This renowned institution recorded its first leukemia trial back in 1999 and has since been at the forefront of innovative research. Not far behind is Boston's Dana-Farber Cancer Institute, which also boasts nine ongoing leukemia trials alongside a remarkable record of 184 previously conducted studies dating back to their inaugural trial in 1993.
Meanwhile, Memorial Sloan Kettering Cancer Center in New York City has made significant contributions as well, currently conducting nine active leukemia trials while having accomplished a noteworthy total of 182 previous investigations since initiating their first trial in 1994. Another notable hospital making strides is MD Anderson Cancer Center once again based in Houston; they have eight ongoing leukemia clinical trials under their belt while having conducted a commendable number154 prior experiments since undertaking their initial investigation into this condition back in 1996.
In addition to these institutions, Massachusettst leukemia, several hospitals across the United States are leading the way. In Houston, M D Anderson Cancer Center stands out with nine active leukemia trials and an impressive 209 completed trials throughout its history. This renowned institution recorded its first leukemia trial back in 1999 and has since been at the forefront of innovative research. Not far behind is Boston's Dana-Farber Cancer Institute, which also boasts nine ongoing leukemia trials alongside a remarkable record of 184 previously conducted studies dating back to their inaugural trial in 1993.
Meanwhile, Memorial Sloan Kettering Cancer Center in New York City has made significant contributions as well, currently conducting nine active leukemia trials while having accomplished a noteworthy total of 182 previous investigations since initiating their first trial in 1994. Another notable hospital making strides is MD Anderson Cancer Center once again based in Houston; they have eight ongoing leukemia clinical trials under their belt while having conducted a commendable number154 prior experiments since undertaking their initial investigation into this condition back in 1996.
In addition to these institutions, Massachusetts General Hospital Cancer Center located in Boston plays an important role too, with seven current leukemia clinical trials and contributing towards advancement through their fifty-seven previously held investigations; theirs can be traced back twenty-four years ago when they began recording such cases way back until 1997.
These hospitals represent not only hope for those affected by leukemia but also exemplify the relentless dedication of medical professionals nationwide who strive to conquer this disease. The combined efforts of these top-tier facilities push us closer toward breakthroughs that will ultimately transform the lives of countless patients battling this formidable illness globally
Which are the best cities for leukemia clinical trials?
When it comes to leukemia clinical trials, several cities are at the forefront of research and development. Boston, Massachusetts leads with 41 active trials focused on treatment options like cytarabine and AZD6738. Houston, Texas closely follows with 35 ongoing studies exploring treatments such as Dasatinib and JAKi Naïve Combination Arm. New York, New York also stands out with 31 active trials investigating treatment options including Dasatinib and JAKi Naïve Combination Arm. In addition, Chicago, Illinois contributes significantly to leukemia research with 27 active trials studying drugs like Dasatinib and Daunorubicin Hydrochloride. Lastly, Los Angeles, Californias Dasatinib and JAKi Naïve Combination Arm. New York, New York also stands out with 31 active trials investigating treatment options including Dasatinib and JAKi Naïve Combination Arm. In addition, Chicago, Illinois contributes significantly to leukemia research with 27 active trials studying drugs like Dasatinib and Daunorubicin Hydrochloride. Lastly, Los Angeles, California offers access to 21 active trials examining various treatment approaches for leukemia patients. These cities serve as hotspots for cutting-edge clinical trials that push the boundaries of leukemia care and bring hope to those affected by this disease.
Which are the top treatments for leukemia being explored in clinical trials?
Leukemia research is making significant strides, with several promising treatments currently being explored in clinical trials. Among the top contenders are dasatinib, a drug that has shown promise in three active trials and boasts an impressive 100 all-time leukemia trials since its introduction in 2001. Another noteworthy contender is ruxolitinib, which is currently being tested in two ongoing trials and has accumulated 29 all-time leukemia trials since its first listing in 2010. Additionally, venetoclax shows great potential with two active trials and an extensive track record of 220 all-time leukemia trials dating back to its initial listing in 2007. These innovative therapies offer hope for improved outcomes for patients battling this challenging disease as researchers strive to uncover new treatment options through rigorous clinical exploratioall-time leukemia trials since its introduction in 2001. Another noteworthy contender is ruxolitinib, which is currently being tested in two ongoing trials and has accumulated 29 all-time leukemia trials since its first listing in 2010. Additionally, venetoclax shows great potential with two active trials and an extensive track record of 220 all-time leukemia trials dating back to its initial listing in 2007. These innovative therapies offer hope for improved outcomes for patients battling this challenging disease as researchers strive to uncover new treatment options through rigorous clinical exploration.
What are the most recent clinical trials for leukemia?
Exciting advancements are underway in the field of leukemia research, with recent clinical trials offering hope for improved treatments. One such trial is investigating Leukemia CNS1 or 2, a phase 2 study aimed at evaluating its effectiveness against leukemia. Additionally, GDX012 has shown promise in dose escalation studies as a potential treatment option for leukemia patients. CB-103 and pirtobrutinib are also being investigated in separate phase 2 trials to assess their efficacy and safety profiles. Finally, an innovative approach involving anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC) is undergoing both Phase 1 and Phase 2 testing as a potential therapy for leukemia. These ongoing trials hold immense potential to improve outcomes and quality of life for individuals battling this challenging disease.
What leukemia clinical trials were recently completed?
In a series of recent advancements in the field of leukemia research, several clinical trials have been successfully completed. Noteworthy among these achievements are the completion of trials for Lemzoparlimab sponsored by AbbVie in June 2021 and Azacitidine sponsored by Pfizer in May 2021. Furthermore, a trial for mRNA-1273 conducted under the National Cancer Institute's sponsorship was finalized in April 2021. These significant milestones demonstrate the ongoing dedication to finding effective treatments for leukemia and offer hope to those affected by this challenging disease.